Parkinson's disease. Parkinson's disease
Conditions
Interventions
Intervention 1: Intervention group: They will receive 5 g/d of synbiotic supplement, Containing Lactobacillus, Bifidobacterium and Streptococcus species and Inulin prebiotic( product of Tak gen zist
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
50 Years to 80 Years
Inclusion criteria
Inclusion criteria: Patients who agree to participate in the study Diagnosis of Parkinson's by a neurologist based on the diagnostic criteria of the Parkinson's Disease Association (UK Parkinson's disease society Brain Bank criteria) Age 50 to 80 years
Exclusion criteria
Exclusion criteria: Regular consumption of products fortified with probiotics and prebiotics, probiotic and prebiotics supplements at least 2 months before start of the study Take antibiotics or laxatives at least 2 months before the start of the study Take antioxidant supplements or supplements that affect the disease Having a history of gastrointestinal surgery History of chronic gastrointestinal disease, hypothyroidism or hyperthyroidism, severe psychosis, or other concomitant neurological diseases, cognitive impairment, smoking or nicotine or alcohol use Having a history of type 1 and 2 diabetes Taking anti-inflammatory and immunosuppressive drugs Sensitivity to the compounds in the supplement Having hoehn and yahr score of 5 out of 5
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Symptome of Parkinson's disease (Motor and non motor). Timepoint: At baseline and after 12 weeks. Method of measurement: Using the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) questionnaire and Calculate the score of the questions and use of them.;Zonulin. Timepoint: At baseline and after 12 weeks. Method of measurement: Enzyme-linked immunosorbent assay (ELISA) kits.;High sensitive C-reactive protein (Hs-CRP). Timepoint: At baseline and after 12 weeks. Method of measurement: Enzyme-linked immunosorbent assay (ELISA) kits.;TNF-a. Timepoint: At baseline and after 12 weeks. Method of measurement: Enzyme-linked immunosorbent assay (ELISA) kits.;Total antioxidant capacity. Timepoint: At baseline and after 12 weeks. Method of measurement: biochemical kit of KiaZist Co.;Total oxidant status. Timepoint: At baseline and after 12 weeks. Method of measurement: biochemical kit of KiaZist Co.;Malodialdehyde. Timepoint: At baseline and after 12 weeks. Method of measurement: biochemical kit of KiaZist Co.;Glutathione. Timepoint: At baseline and after 12 weeks. Method of measurement: biochemical kit of KiaZist Co.;Disease stage progression. Timepoint: At baseline and after 12 weeks. Method of measurement: Hoehn and yahr scale.;Lipopolysaccharid (endotoxin). Timepoint: At baseline and after 12 weeks. Method of measurement: Enzyme-linked immunosorbent assay (ELISA) kits. | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life. Timepoint: at baseline and after 12 week. Method of measurement: Parkinson's Disease Questionnaire - 39.;Dietary intake. Timepoint: at baseline, Week six and twelve. Method of measurement: food record.;Depression and anxiety. Timepoint: At baseline and after 12 weeks. Method of measurement: beck depression questionnaire and hospital anxiety and depression scale.;Fatigue. Timepoint: At baseline and after 12 weeks. Method of measurement: Fatigue severity scale questionnaire.;Body mass index. Timepoint: At baseline and after 12 weeks. Method of measurement: It will calculated by weight divided by height (in meters).;Weight. Timepoint: At baseline and after 12 weeks. Method of measurement: Standard weight scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contactsanaz mehrabani
Esfahan University of Medical Sciences
Outcome results
None listed